Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF versus CLARITIN D.
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF vs CLARITIN-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective histamine H1-receptor antagonist. It inhibits the H1 receptor, reducing histamine-mediated effects such as edema, flare, and pruritus.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
5 mg or 10 mg orally once daily; maximum 10 mg per day.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8.3 hours in healthy adults; prolonged to ~20 hours in renal impairment (CrCl <30 mL/min).
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% is eliminated in feces.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination